Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Kinnate Biopharma Inc. - Common Stock (NQ:KNTE)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Apr 2, 2024 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	0
Open	-
Bid (Size)	2.650 (47)
Ask (Size)	2.670 (37)
Prev. Close	2.650
Today's Range	N/A - N/A
52wk Range	N/A - N/A
Shares Outstanding	44,145,579
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

XOMA Corporation Announces Closing of Tender Offer

April 03, 2024

Kinnate Stockholders to Receive $2.5879 Per Share in Cash Plus Contingent Value Right

From XOMA Corporation

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Kinnate Biopharma Inc. (Nasdaq – KNTE)

March 25, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

Performance

More News

XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.

March 19, 2024

From XOMA Corporation

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), Societal CDMO Check Corp. (Nasdaq –

March 19, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

KINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE

March 13, 2024

From Kahn Swick & Foti, LLC

Via Business Wire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), Societal CDMO Check Corp. (Nasdaq – SCTL), California BanCorp (Nasdaq – CALB)

March 13, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories

March 01, 2024

From Kinnate Biopharma; Pierre Fabre Laboratories

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AVROBIO, Inc. (Nasdaq – AVRO), Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), California BanCorp (Nasdaq – CALB)

February 26, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: VIZIO Holding Corp. (NYSE - VZIO), HireRight Holdings Corporation (NYSE – HRT), Kinnate Biopharma Inc. (Nasdaq – KNTE), California BanCorp (Nasdaq – CALB)

February 20, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

KINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE

February 19, 2024

From Kahn Swick & Foti, LLC

Via Business Wire

Biotech Royalty Aggregator XOMA To Acquire Small Cancer-Drug Developer Kinnate Biopharma ↗

February 16, 2024

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: HireRight Holdings Corporation (NYSE – HRT), Kinnate Biopharma Inc. (Nasdaq – KNTE), AVROBIO, Inc. (Nasdaq – AVRO), California BanCorp (Nasdaq – CALB)

February 16, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

KNTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Kinnate Biopharma Inc. Is Fair to Shareholders

February 16, 2024

From NEW YORK

Via Business Wire

Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Share

February 16, 2024

From Kinnate Biopharma

Via GlobeNewswire

XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right

February 16, 2024

From XOMA Corporation

Via GlobeNewswire

Why Shapeways Holdings Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

November 15, 2023

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

November 15, 2023

Via Benzinga

Kinnate Biopharma Inc. (NASDAQ: KNTE) is One of Wednesday Morning’s Most Active Stocks

November 15, 2023

Via Investor Brand Network

Why is Cancer-Focused Kinnate Biopharma Stock Trading Higher Today? ↗

November 15, 2023

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 15, 2023

Via Benzinga

Kinnate Biopharma Inc. Reports Third Quarter 2023 Financial Results and Recent Corporate Updates

November 09, 2023

From Kinnate Biopharma

Via GlobeNewswire

Analysts Move To Sidelines For Cancer Player Kinnate Biopharma After Restructuring ↗

September 19, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 19, 2023 ↗

September 19, 2023

Via Benzinga

Why Is Cancer Firm Kinnate Biopharma Stock Trading Lower Today? ↗

September 19, 2023

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

September 19, 2023

Via Benzinga

Frequently Asked Questions

Is Kinnate Biopharma Inc. - Common Stock publicly traded?

Yes, Kinnate Biopharma Inc. - Common Stock is publicly traded.

What exchange does Kinnate Biopharma Inc. - Common Stock trade on?

Kinnate Biopharma Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Kinnate Biopharma Inc. - Common Stock?

The ticker symbol for Kinnate Biopharma Inc. - Common Stock is KNTE on the Nasdaq Stock Market

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.